Ann: Investor Presentation-CCV.AX, page-9

The questions from J Stewart (Hartleys) in my notes above indicate he was building back from the NPAT guidance to get a EBITDA, then inferrring sales and then ultimately a 2016-17 price target so Hartleys are the ones to keep an eye on but that report would have to have been released in the last couple of days to be current so not sure it exists yet.

Its quite obvious what it will say though. Reasonable profit forecast, massive uncertainty on the transition to MACC which is what will underpin future growth. Aside from MNY who are the major competitors in this space? Strong position in Aust with access to capital to expand into NZ (an interesting question would be: do they have a first mover advantage in the NZ MACC market?) I'd say CCV can afford to buy market share in Aust if thats what they choose to do so watch out MNY.